The Role of Intensive Chemotherapy in Myelodysplastic Syndromes

References

• Cheson B. D., Jasperse D. M., Simon R., Friedman M. A. A critical appraisal of low dose Ara C in patients with acute non lymphocytic leukemia and myelodysplastic syndromes. J. Clin. Oncol 1986; 4: 1857–1864
   PubMed Web of Science ®Google Scholar
• Kobayashi Y., Okada T., Ozawa K. Treatment of myelodysplastic syndromes with recombinant granulocyte colony stimulating factor. A preliminary report. Am. J. Med. 1989; 86: 178–182
   PubMed Web of Science ®Google Scholar
• Appelbaum F., Barrall J., Storb R., et al. Bone marrow transplantation for patients with myelodysplasia: pretreatment variables and outcome. Ann. Int. Med. 1990; 112: 590–597
   PubMed Web of Science ®Google Scholar
• Armitage J. O., Dick F. R., Needleham S. W., Burns C. P. Effect of chemotherapy for the myelodysplastic syndrome. Cancer Treat. Rep. 1981; 65: 601–605
   PubMedGoogle Scholar
• Keating M., McCredie K., Benjamin R., et al. Treatment of patients over 50 years of age with acute myelogenous leukemia by a combination of rubidazone. Ara C., vincristine and prednisone (ROAP). Blood 1981; 58: 584–491
   PubMed Web of Science ®Google Scholar
• Mertelsmann R., Thaler H. T., To L., et al. Morphological classification, response to therapy and survival in 263 adult patients with acute non lymphoblastic leukemia. Blood 1980; 56: 773–7781
   PubMed Web of Science ®Google Scholar
• Martiat P., Ferrant A., Michaux J. L., Sokal G. Intensive chemotherapy for acute nonlymphoblastic leukemia after primary myelodysplastic syndrome. Hematol. Oncol. 1989; 7: 307–17
   PubMed Web of Science ®Google Scholar
• Hoyle C., De Bastos C., Wheatley K., et al. AML associated with previous chemotherapy. MDS or myeloproliferative disorfers: results from the MRC's 9th AML trial. Brit. J. Haematol 1989; 72: 45–53
   PubMed Web of Science ®Google Scholar
• Gajewski J., Ho W., Nimer S., et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J. Clin. Oncol 1989; 7: 1637–1645
   PubMed Web of Science ®Google Scholar
• Preisler H., Raza A., Barcos M. High dose cytosine arabinoside in the treatment of preleukemic disorders. Am. J. Hematol 1986; 23: 131–134
   PubMed Web of Science ®Google Scholar
• De Witte T., Muus P., De Pauw B., Haanen C. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 1990; 66: 831–837
   PubMed Web of Science ®Google Scholar
• Tricot G., Boogaerts M. A. The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Brit. J. Haematol 1986; 63: 477–483
   PubMed Web of Science ®Google Scholar
• Fenaux P., Morel P., Rose C., et al. Prognostic factors in adult de ovo myelodysplastic syndromes treated by intensive chemotherapy. Brit. J. Haematol 1991; 11: 497–501
   Google Scholar
• Michels S., Saumur J., Arthur D., Robinson L., Brunning R. Refractory anemia with excess of blasts in transformation. Hematologic and clinical study of 52 patients. Cancer 1989; 64: 2340–2346
   PubMed Web of Science ®Google Scholar
• Runde V., Aul C., Heyll A., Schneider W. Intensive antileukemic treatment of advanced primary myelodysplastic syndromes. Xlth Meeting of the International Society of Hematology, Basel, 1991; 57
   Google Scholar
• Bloomfield C. Acute leukemias. Education program of the American Society of Hematology. Boston 1990
   Google Scholar
• Ohno R., Tomonaga M., Kobayashi T., et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. New Engl. J. Med 1990; 323: 871–7
   PubMed Web of Science ®Google Scholar
• Tefferi A., Thibodeau S. N., Sorberg L. A. Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. Blood 1990; 75: 1770–1773
   PubMed Web of Science ®Google Scholar
• Abrahamson G., Boultwood J., Madden J., et al. Clonality of cell populations in refractory anaemia using combined approach of gene loss and X-linked restriction fragment length polymorphism-methylation analyses. Brit. J. Haematol 1991; 79: 550–555
   PubMed Web of Science ®Google Scholar
• Culligan D., Padva R., Jacobs A. Evidence for lineage restriction in some cases of MDS. Blood 1991; 78(suppl. 1)381a, Abstr.
   Google Scholar
• Fearon E., Burke P., Schiffer C., et al. Differentiation of leukemia cells to mature. Leukocytes in patients with acute nonlymphocytic leukemia. N. Engl. J. Med. 1986; 315: 15–24
   PubMed Web of Science ®Google Scholar
• Wormann B., Safford M., Konemann S., et al. Detection of residual leukemic cells in AML patients in complete remission. Blood 1991; 78(suppl. 1)381a
   Google Scholar
• Levine E., Blommfield C. Secondary myelodysplastic syndromes and leukemias. Clin. Haematol 1986; 4: 1037–1080
   Google Scholar
• Kantarjian H. M., Keating M. J., Walters R. S., et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J. Clin. Oncol 1986; 4: 1748–1757
   PubMed Web of Science ®Google Scholar
• Michels S. D., McKenna R. W., Arthur D. C., Brunning R. D. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: A clinical and morphologic study of 65 cases. Blood 1985; 65: 1364–1372
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Philip P., Larsen S. O., Jensen G., Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 1990; 76: 1083–1091
   PubMed Web of Science ®Google Scholar
• Brusamolino E., Papa G., Valagussa P., et al. Treatment-related leukemia in Hodgkin's disease: a multi-institution study on 75 cases. Hematol. Oncol 1987; 5: 83–98
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Keating M., Walters R., et al. The association of specific “favorable” cytogenetic abnormalities with secondary leukemia. Cancer 1986; 58: 924–927
   PubMed Web of Science ®Google Scholar
• Fenaux P., Lucidarme D., Lai J. L., Bauters F. Favorable cytogenetic abnormalities in secondary leukemia. Cancer 1989; 63: 2505–2508
   PubMed Web of Science ®Google Scholar
• Fenaux P., Lai J. L., Quiquandon I., et al. Therapy related myelodysplastic syndrome and leukemia with no “unfavourable” cytogenetic findings have a good response to intensive chemotherapy: A report on 15 cases. Leukemia and Lymphoma 1991; 5: 117–125
   PubMed Web of Science ®Google Scholar